Risk-Targeted Behavioural Activation for the Management of Treatment-Resistant Depression.
Launched by MCGILL UNIVERSITY · Dec 8, 2024
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
Objective: The purpose of the present study was to examine the acceptability and impact of a standardized 10-week risk-targeted behavioral activation (RTBA) intervention as an augmentation strategy in the clinical management of treatment-resistant depression (TRD). Methods: The study sample consisted of 118 individuals with TRD, who were currently absent from work and referred to an occupational rehabilitation service. The RTBA intervention was a 10-week standardized program consisting of weekly visits with a trained clinician. The objectives of treatment included symptom reduction, resumpt...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • A diagnosis of Major Depressive Disorder
- • The date of diagnosis of MDD preceded referral by at least 12 months
- • At least one previous prescription of an antidepressant failed to yield therapeutic response
- • Currently taking an antidepressant
- • A PHQ9 score in the moderate to severe range of depression at the time of enrolment
- Exclusion Criteria:
- • - Participating in another psychotherapeutic intervention.
About Mcgill University
McGill University, a prestigious research institution located in Montreal, Canada, is committed to advancing medical science through innovative clinical trials. Renowned for its rigorous academic standards and collaborative approach, McGill fosters a dynamic environment that integrates cutting-edge research with clinical practice. With a focus on improving patient outcomes, the university's clinical trials span a wide range of therapeutic areas, leveraging the expertise of its diverse faculty and state-of-the-art facilities. McGill University is dedicated to ethical research practices and the dissemination of knowledge, ensuring that findings contribute meaningfully to the global healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montreal, Quebec, Canada
Patients applied
Trial Officials
Michael Sullivan, PhD
Principal Investigator
McGill University
Heather Adams, BSW
Study Director
Dalhousie University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported